Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Sirolimus Stories

15c3792dd8efea62510f42f9486889e31
2009-04-21 08:14:35

In a small, early clinical trial, researchers at the University of Chicago Medical Center have found that combining eight ounces of grapefruit juice with the drug rapamycin can increase drug levels, allowing lower doses of the drug to be given. They also showed that the combination can be effective in treating various types of cancer. For two decades, pharmacists have pasted DO-NOT-TAKE-WITH-GRAPEFRUIT-JUICE stickers on various pill bottles because it can interfere with the enzymes that break...

2009-03-30 15:01:00

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has been...

2009-03-30 14:59:00

The U.S. Food and Drug Administration says it has approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer. Renal cell cancer, the most common type of kidney cancer, originates in the lining of the small tubules in the kidney that filter waste products from the blood. Afinitor provides an option for patients with advanced renal cell cancer after failure of treatment with the cancer therapies sunitinib (Sutent) or sorafenib (Nexavar), said Dr....

2009-03-23 06:30:00

CALGARY, March 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced results of two preclinical studies that were presented at the Fifth International Meeting on Replicating Oncolytic Virus Therapeutics. The meeting was held in Banff, Alberta from March 18th to 22nd, 2009. Professor Hardev Pandha of the University of Surrey County Hospital, U.K., delivered a poster presentation entitled "Combination of Oncolytic Reovirus and Rapamycin in a B16.F10 Mouse...

2009-03-13 10:23:29

A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer. The discovery was made using a new research model, using mice, which replicates many aspects of human bladder cancer. The model also enabled the researchers to demonstrate that two major tumor suppressor genes, p53 and PTEN, are inactivated in invasive bladder cancer. The findings and this new model are described in a paper in the March...

2009-03-10 08:00:00

Interventional Radiologists Help Peripheral Arterial Disease (PAD) Patients With Critical Limb Ischemia Avoid Amputation SAN DIEGO, March 10 /PRNewswire-USNewswire/ -- Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to...

2009-02-10 10:17:55

A new drug that blocks cancer's main source of growth has been created in the lab and proven effective in mice, scientists are reporting. It is now being readied for clinical trials in patients. Far more potent than similar compounds already in clinical trial, the drug short-circuits the normal ability of cells to sense the need to grow and divide -- a signal that cancer cells exploit to spread in the body. The scientists are working with clinicians to test the drug's effectiveness against a...

2009-01-15 12:23:00

WARREN, N.J., Jan. 15 /PRNewswire/ -- The Court of Appeals for the Federal Circuit in Washington, D.C. today found Boston Scientific Corporation's Ding patent invalid, and reversed a 2005 jury finding that Cordis Corporation's CYPHER(R) Sirolimus-eluting Coronary Stent infringed that patent. Cordis is very pleased with this significant Court decision. The original jury verdict was rendered in July 2005 in Wilmington, Delaware. The Ding patent had claimed a two-layer drug coating for a...

2008-12-12 23:30:46

A British oncologist says he is dismayed that kidney cancer patients may be denied four new treatments due to cost. Dr. Tim Eisen of the University of Cambridge reports in BJU International that the National Institute for Health and Clinical Excellence has provisionally decided sunitinib, sorafenib, temsirolimus and interferon plus bevacizumab are too costly. While none of these new drugs cure the condition, they sometimes can extend life, Eisen said. For instance, some patients taking...

2008-11-06 09:00:45

UNION CITY, Calif., Nov. 6 /PRNewswire/ -- MacuSight(TM), a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced the appointment of Gerald Wroblewski as the company's vice president of operations. Mr. Wroblewski brings MacuSight critical operational expertise in the areas of manufacturing, product supply chain management, packaging and quality assurance. At MacuSight, he will be responsible for overseeing functions related to each...